Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Genitourinary System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm

Cancer Family

Genitourinary System Neoplasm

CI-CAN-00000018Explore in graph →

Non-malignant3,849 active trials61 approved drugs306 evidence items

NCIt: C156482

Overview
Statistics
Survival
Genomics114
Variants & evidence306
Drugs75
Trials17388
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (892)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 751–775 of 892 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genotype-phenotype correlations in von Hippel-Lindau disease.
· Hum Mutat · 2007 · PMID 17024664 · validated civic_curation pubmed
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
· Cancer Discov · 2014 · PMID 24934408 · validated civic_curation pubmed
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
· Pediatr Blood Cancer · 2018 · PMID 29893456 · validated civic_curation pubmed
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
· Cancer Discov · 2023 · PMID 37377403 · validated civic_curation pubmed
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
· Cancer Discov · 2014 · PMID 24625776 · validated civic_curation pubmed
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
· Eur Urol · 2016 · PMID 25636205 · validated civic_curation pubmed
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
· J Clin Invest · 2016 · PMID 27159395 · validated civic_curation pubmed

Showing 751–775 of 892 publications

← Previous
1
…
30
31
32
…
36
Next →

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed

Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe.

· Hum Genet · 1996 · PMID 8707293 · validated civic_curation pubmed

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

· Am J Hum Genet · 1994 · PMID 7977367 · validated civic_curation pubmed

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.

· Mod Pathol · 2018 · PMID 29099503 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.

· Front Pharmacol · 2014 · PMID 24782778 · validated civic_curation pubmed

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

· Cancer Chemother Pharmacol · 2009 · PMID 18607592 · validated civic_curation pubmed

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

· Gynecol Oncol · 2006 · PMID 16487996 · validated civic_curation pubmed

A novel K-ras mutation in colorectal cancer. A case report and literature review.

· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor.

· Obstet Gynecol · 2016 · PMID 26942346 · validated civic_curation pubmed

Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.

· Pharmacogenetics · 2001 · PMID 11505222 · validated civic_curation pubmed

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed

Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

· Am J Surg Pathol · 2005 · PMID 15644781 · validated civic_curation pubmed

Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.

· Clin Cancer Res · 2009 · PMID 19228722 · validated civic_curation pubmed

Immunophenotype-Genotype Correlations in Clear Cell Sarcoma of Kidney-An Evaluation of Diagnostic Ancillary Studies.

· Pediatr Dev Pathol · 2020 · PMID 32364435 · validated civic_curation pubmed

Mutually exclusive BCOR internal tandem duplications and YWHAE-NUTM2 fusions in clear cell sarcoma of kidney: not the full story.

· J Pathol · 2016 · PMID 27000436 · validated civic_curation pubmed

Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion.

· Histopathology · 2018 · PMID 28833375 · validated civic_curation pubmed